These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 11983261)

  • 21. Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
    Rosario M; Fulkerson J; Soneji S; Parker J; Im EJ; Borthwick N; Bridgeman A; Bourne C; Joseph J; Sadoff JC; Hanke T
    J Virol; 2010 Aug; 84(15):7815-21. PubMed ID: 20484495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa.
    Nkolola JP; Wee EG; Im EJ; Jewell CP; Chen N; Xu XN; McMichael AJ; Hanke T
    Gene Ther; 2004 Jul; 11(13):1068-80. PubMed ID: 15164090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors.
    Hopkins R; Bridgeman A; Bourne C; Mbewe-Mvula A; Sadoff JC; Both GW; Joseph J; Fulkerson J; Hanke T
    Eur J Immunol; 2011 Dec; 41(12):3542-52. PubMed ID: 21932450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.
    Amara RR; Villinger F; Staprans SI; Altman JD; Montefiori DC; Kozyr NL; Xu Y; Wyatt LS; Earl PL; Herndon JG; McClure HM; Moss B; Robinson HL
    J Virol; 2002 Aug; 76(15):7625-31. PubMed ID: 12097576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.
    Dorrell L; Yang H; Ondondo B; Dong T; di Gleria K; Suttill A; Conlon C; Brown D; Williams P; Bowness P; Goonetilleke N; Rostron T; Rowland-Jones S; Hanke T; McMichael A
    J Virol; 2006 May; 80(10):4705-16. PubMed ID: 16641264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.
    Bauer A; Podola L; Mann P; Missanga M; Haule A; Sudi L; Nilsson C; Kaluwa B; Lueer C; Mwakatima M; Munseri PJ; Maboko L; Robb ML; Tovanabutra S; Kijak G; Marovich M; McCormack S; Joseph S; Lyamuya E; Wahren B; Sandström E; Biberfeld G; Hoelscher M; Bakari M; Kroidl A; Geldmacher C
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28701395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
    Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
    PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen.
    Hanke T; Samuel RV; Blanchard TJ; Neumann VC; Allen TM; Boyson JE; Sharpe SA; Cook N; Smith GL; Watkins DI; Cranage MP; McMichael AJ
    J Virol; 1999 Sep; 73(9):7524-32. PubMed ID: 10438842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in Mice.
    Jongwe TI; Chapman R; Douglass N; Chetty S; Chege G; Williamson AL
    PLoS One; 2016; 11(7):e0159141. PubMed ID: 27427967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen.
    Allen TM; Vogel TU; Fuller DH; Mothé BR; Steffen S; Boyson JE; Shipley T; Fuller J; Hanke T; Sette A; Altman JD; Moss B; McMichael AJ; Watkins DI
    J Immunol; 2000 May; 164(9):4968-78. PubMed ID: 10779808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.
    Horton H; Vogel TU; Carter DK; Vielhuber K; Fuller DH; Shipley T; Fuller JT; Kunstman KJ; Sutter G; Montefiori DC; Erfle V; Desrosiers RC; Wilson N; Picker LJ; Wolinsky SM; Wang C; Allison DB; Watkins DI
    J Virol; 2002 Jul; 76(14):7187-202. PubMed ID: 12072518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol.
    Ramsburg E; Rose NF; Marx PA; Mefford M; Nixon DF; Moretto WJ; Montefiori D; Earl P; Moss B; Rose JK
    J Virol; 2004 Apr; 78(8):3930-40. PubMed ID: 15047809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost.
    Joachim A; Ahmed MIM; Pollakis G; Rogers L; Hoffmann VS; Munseri P; Aboud S; Lyamuya EF; Bakari M; Robb ML; Wahren B; Sandstrom E; Nilsson C; Biberfeld G; Geldmacher C; Held K
    Front Immunol; 2020; 11():719. PubMed ID: 32411138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.
    Viegas EO; Kroidl A; Munseri PJ; Missanga M; Nilsson C; Tembe N; Bauer A; Joachim A; Joseph S; Mann P; Geldmacher C; Fleck S; Stöhr W; Scarlatti G; Aboud S; Bakari M; Maboko L; Hoelscher M; Wahren B; Robb ML; Weber J; McCormack S; Biberfeld G; Jani IV; Sandström E; Lyamuya E;
    PLoS One; 2018; 13(11):e0206838. PubMed ID: 30496299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B.
    Perdiguero B; Raman SC; Sánchez-Corzo C; Sorzano COS; Valverde JR; Esteban M; Gómez CE
    Viruses; 2018 Aug; 10(8):. PubMed ID: 30104537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons.
    Burgers WA; Chege GK; Müller TL; van Harmelen JH; Khoury G; Shephard EG; Gray CM; Williamson C; Williamson AL
    J Gen Virol; 2009 Feb; 90(Pt 2):468-480. PubMed ID: 19141458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
    Hanke T; McMichael AJ; Dorrell L
    J Gen Virol; 2007 Jan; 88(Pt 1):1-12. PubMed ID: 17170430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterologous prime-boost vaccination with DNA and MVA vaccines, expressing HIV-1 subtype C mosaic Gag virus-like particles, is highly immunogenic in mice.
    Chapman R; Jongwe TI; Douglass N; Chege G; Williamson AL
    PLoS One; 2017; 12(3):e0173352. PubMed ID: 28278263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.
    Amara RR; Villinger F; Altman JD; Lydy SL; O'Neil SP; Staprans SI; Montefiori DC; Xu Y; Herndon JG; Wyatt LS; Candido MA; Kozyr NL; Earl PL; Smith JM; Ma HL; Grimm BD; Hulsey ML; Miller J; McClure HM; McNicholl JM; Moss B; Robinson HL
    Science; 2001 Apr; 292(5514):69-74. PubMed ID: 11393868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.